Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
List view / Grid view
University of Harvard’s Wyss Institute
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.